Disease Control and Prevention Vaccine Market Size, Share, By Vaccine Type (Monovalent Vaccine and Multivalent Vaccine), By Product Type (Live-attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), By Age Group (Pediatric, and Adults), By Application (Infectious Disease, Cancer, and Other Indication) and By Region - Trends, Analysis and Forecast till 2034

Disease Control and Prevention Vaccine Market Size was valued at USD 9.0 Billion in 2024 and is expected to reach USD 10.3 Billion by 2034, growing at a CAGR of 1.5%.

The market for DCP vaccines is set to skyrocket, driven by a highly dynamic interface of forces. At the forefront lies the relentless pursuit of innovation in vaccine development. Pharmaceutical companies are harnessing their investments in research to ensure approvals for next-generation defenses against common and not-so-prevalent infectious diseases. Now this commitment to science and moving it to the next level takes the focus of the 2017 FDA approval of Shingrix, a breakthrough shingles vaccine representing major progress in adult vaccination. But the pipeline with new vaccines to treat a wide venue of conditions, at the same time, it is full of hope in offering yet still more advances in the future. And with continuing creation of new breakthrough vaccines, hopefully the growth of the vaccine market through DCP will continue to accelerate. But innovation is only one factor in the entire equation. Another driving factor that more critically propels the market is the increasing focus on expanding the access to vaccines. This surge in bridging the gap in such availability of these kinds of tools may quite possibly save people's lives and is almost of the greatest interest to a lot of governments and private organizations. A typical good example is Uganda, where in 2018, the government rolled off a program to administer free rotavirus vaccines to children under five, thereby protecting them from diarrhea—a major killer of children. Such programs do not only expand the outcomes of public health but also create markets hitherto untapped because they have been underserved. This public–private collaborative effort can thus be expected to majorly boost market growth for DCP vaccines.

Another factor that drives market expansion is growing public health awareness towards preventive measures such as vaccinations. With mass awareness created among the public for vaccination benefits, the demand for DCP vaccines to get preventive measures is expected to surge systematically. Furthermore, the global burden from infectious diseases is likely to rise, throwing up further challenges to both healthcare providers and those in policy circles focusing on vaccination programs. This additional complemented increase due to greater disposable incomes within developing countries will be expected to aid in the increase in the overall size of the DCP vaccine market. In conclusion, huge are the stakes for the DCP vaccines market due to a variety of factors. Such advancements in vaccine development, rigorous push for vaccine access, and rising awareness in public health bring a new day where preventive health care will have a more promising future, resulting in positive global health outcomes.

Key Drivers of Target Market:

Innovation Engine: Powerhouse of New Vaccines

• The pharmaceutical industry is investing vast sums of money in research and development to produce a steady stream of new vaccines. Coupled with this, of course, is a thrust of technological advancement; one need only consider the new triumphs in care for shringrix and the zoster vaccine that is utterly radical. Beyond this specific example, the powerful pipeline of vaccines that target diverse diseases like cancer holds tremendous promise. This constant flow of new vaccines with improved efficacy and wider safety spectra is bound to significantly enhance the DCP vaccine market.
• A modest access to vaccines that have developed in poor countries has long remained an enigma. In realization of this, currently, governments and private organizations are focusing increasingly on initiatives that bridge the identified gap and ensure wider vaccine availability. Amp strong example is the 2018 program in Uganda that aims to provide free rotavirus vaccines to children aged lower than five years. These vaccines not just empower public health by saving the vulnerable populations from preventable diseases but also result in market expansion by reaching these previously underserved communities. This collective push between public and private sectors to increase vaccine access is positioned to act as a powerful driver of growth for the DCP vaccine market
• The enormous power of the bar, state health consciousness, vis-a-vis vaccination, is on the rise. As the indication state is increasingly made aware of the value of immunization and how it can prevent killer diseases, the need for preventive measures such as the DCP vaccine is expected to rise. This sense of state sensing is blowing away freely available information and informative campaigns that help individuals make informed decisions about their health.

Global effect of contagious diseases

• The Constructing effect of contagious diseases round the man is suggestion healthcare professionals and policymakers to prioritize inoculation programs. This urgency stems from the alarming rise in vaccine-preventable illnesses in some regions and the eCombinence of new infectious threats. DCP Vaccines Bid Amp Right Drive To Fight These Threats Up To Amp Rush Inch Take From Healthcare Institutions And Governments Quest To Tone Their State Health Defenses
• Disposable income along the rise - as disposable incomes rise in developing nations affordability becomes lower of and and barrier to vaccination. This economic growth enables individuals and families to afford preventive healthcare, including vaccinations for themselves and their children. this reduction combined with Building healthcare awareness is likely to contribute significantly to the overall growth of the dcp vaccine market.

Restrains:

Complexities surrounding the DERs:

High Cost of Vaccines and Distribution Challenges

• Vaccines can be expensive in development, production, and distribution, driving the price up for healthcare providers and governments, in the end possibly impeding access in resource-challenged settings. Furthermore, some vaccines entail cold chain logistics that are put in place at a high cost and, therefore, form a logistical hurdle for areas where infrastructure is poor.
• Around much of the globe, vaccine hesitancy and skepticism are still problems, even in the face of the obvious increases in knowledge about public health indicators. Misinformation and mistrust in scientific bodies may sometimes lead to vaccine refusal that would place in danger the general vaccine coverage of a country, hence remaining susceptible to outbreaks. This involves developing strategies of public communication for dealing with public worries by being transparent and providing evidence-based information.

Limited Profitability in Low-Income Settings

• There is, therefore, little added incentive for vaccine development companies to find vaccines for diseases that mainly affect low-income countries. Low profit margins in places like these become a disincentive for research and development into diseases that affect the very poor.
• Political instability in some developing countries and weak healthcare infrastructure act as major hindrances to the effectiveness of vaccination programs. Civil unrest commonly results in the worst conditions, with a shortage of adequate personnel who are adequately trained, and poor storage and transport facilities.
• Emerging Infectious Diseases and Evolving Pathogens The rapid emergence of new infectious diseases is enough cause for challenge, and the constant evolution of existing pathogens makes vaccine development almost impossible. Developing and deploying effective vaccines fast enough to stay one step ahead is still indeed a formidable challenge.

Opportunities:

New Developments Coming in Next-Gen Vaccines

• There are new opportunities loaded all the time with vaccine technologies. Such developments include thermos-stabilization (vaccines that don't need stringent cold-chain storage), multivalent vaccines (more than one strain in one vaccine), and needle-free administration, enhancing accessibility and reach.

Public-Private Collaboration for Global Access

• The collaboration between governments, international bodies, and pharmaceutical companies will have a critical role in ensuring the equitable delivery of vaccines in low- and middle-income countries. Innovative financing approaches and technology transfer will be essential in closing the affordability gap and ensuring that increased amounts of life-saving vaccines are supplied.

Focus on Neglected Tropical Diseases

• A variety of neglected tropical diseases disproportionately afflict low-income populations. Developing and improving cost-effective vaccines targeting these diseases with increased focus can lead to significant public health impact as well as a new market segment for the pharmaceutical companies.

Customized Vaccination Programs

• The growing field of personalized medicine opens up opportunities for the development of tailor-made vaccination programs according to the specific needs and immune responses of the user. In that light, this method could really be applied in the improvement of vaccine efficacy or in addressing the apprehension against over-vaccination.

Digital Technologies for Improved Delivery

• The use of such digital tools as vaccine registries, electronic health records, and logistic tracking systems will drive a vaccination delivery revolution. It is then going to ascertain efficiency, proper handling, storage, and an increase in collection for evaluating the program.

The market is segmented based on By Vaccine Type, By Product type, By Age Group, By Application, and Region.

Vaccine Type Insights:

• Monovalent Vaccines: These are vaccines developed to provide protection against a solitary strain or serotype of a bacterium or virus. For example, the seasonal influenza vaccine is a monovalent vaccine prepared to protect against the most prevalent strain of influenza virus expected during the season.
• Multivalent Vaccines: In contrast, multivalent vaccines provide broader protection defenses against several strains or serotypes of a virus or bacteria. This is particularly useful with diseases that exhibit high amounts of type variation, such as the pneumococcal disease, Human Papillomavirus, and others.

Product Type Insights:

• Live-attenuated Vaccines contain live attenuated virus or bacteria, which really means the virus or bacteria are highly weakened organisms. These replica agents provoke a reaction with the immune system that leads to a robust and long-lasting immune response. Examples of live-attenuated vaccines are the measles, mumps, and rubella (MMR) vaccine and the varicella vaccine for chickenpox.
• Inactivated Vaccines: A vaccine that contains a dead virus or bacteria, or components of them, which cannot cause the disease itself. Although inactivated vaccines still elicit an immune response, in some cases, unlike a live-attenuated vaccine, more than one dose is required. Examples include polio and hepatitis A vaccines.
• Recombinant Vaccines: It is a high-end concept in which the use of recombinant technology aids in designing specific antigens, translating into parts of the virus or bacteria for immune recognition. Advantages of recombinant vaccines include high purity, safety, and selective activity toward antigens so that it is more specific in the kind of immune response elicited. An example will be the vaccine Shingrix for shingles.
• Toxoid Vaccines These vaccines target toxins produced by bacteria, rather than the bacteria itself. The toxin is modified (rendered toxoid) so that it cannot cause disease but will still trigger the immune system to produce antibodies against the toxin. The classic example is the tetanus toxoid vaccine.

Age group Insights:

• Pediatric Vaccines: This is a category that deals with vaccines that apply for children who are beyond the age of infancy but are not yet in their adolescent stage. This group of vaccines is an important part of defense against infectious diseases that children have to come across as they continue growing. Eg. Diphtheria, tetanus and pertussis; measles, mumps and rubella.
• Adult Vaccines: In this section, you have been educated on the various vaccines that are recommended across the lifespan in adulthood. Adult vaccination plays a critical role in the prevention of disease and in lifelong health, and further contributes to abating diseases that may make a reappearance in life. Examples are influenza vaccine, tetanus booster shot, and Shingrix vaccine for herpes zoster.

Application Insights:

• Infectious Disease Vaccines: This is the largest segment that includes vaccines for the prevention of infectious diseases caused by viruses, bacteria, and parasites. For instance, the importance of these types of vaccines is to control outbreaks and the lessening of diseases which cause a rise in global health outcomes. Examples include polio vaccine, hepatitis B vaccine, and HPV vaccine.
• Cancer Vaccines: This section refers to vaccines that may prevent specific cancers or are possibly linked to cancer treatment. Though still in a developing age, vaccination heralds a huge promise in the future of cancer prevention and management. The best classic example here is the HPV vaccine for cervical cancer and the hepatitis B vaccine for prevention of liver cancer.
• Other Indications This section involves all the vaccines that are used for other applications besides infectious diseases and cancer. For example, there are travel vaccines that are used in the case of diseases present in certain regions, whereas some are used as allergy vaccines to treat allergies.

Regional Insights

• North America: The North America: North America is the largest regional market for DCP vaccines, with the United States and Canada having large volumes of vaccines and strong health infrastructures. Important investments take place through strong regulatory frameworks and with much in research and development. Together, this results in high rates of vaccination for routine childhood immunizations and a strong presence of major pharmaceutical companies driving innovation in vaccine development. But, in the larger picture, it is important to ensure the equitable availability of vaccines for all populations and to address vaccine hesitancy in some of the populations.
• Europe: It is evident that the European DCP vaccine market is mature and technology-savvy. Public health emerges as an important concern in most of the countries in Europe. Here, universal health care systems ensure that necessary vaccination programs are generalized among the citizens. In addition, it is known for preventive healthcare, associated with well-regulated processes which in turn have caused a high rate of vaccination coverage. However, the European market also deals with issues related to vaccine hesitancy and skepticism, in addition to multiple complex pricing and reimbursement structures for vaccines.
• Asia Pacific: This huge and diverse region confers great potential for the growth of the DCP vaccine market. Countries like China and India, with their large populations and developing middle class, have seen huge economic development and therefore augmentation of the spending powers on healthcare. This has, in turn, resulted in more demand for vaccines and raised investments for the production of vaccines within the country. On the contrary, there are massive discrepancies in vaccination coverage in the region. Developing nations within Asia-Pacific are troubled by poor infrastructure, resource inadequacies, and weak health systems, which bar the effective implementation of mass vaccination programs.
• Latin America is among the hotbeds of the DCP vaccines market, driven by a growing middle class with increased disposable income and renewed attention to health. Most of the countries in the region are taking action to increase vaccination coverage and access to key vaccines through the launch of initiatives. However, discrepancies within the region are huge, and in some countries, major challenges include healthcare infrastructure that is not widely available, difficulties in vaccine procurement, and hesitancy toward vaccination.
• Middle East and Africa: DCP vaccines were found to have a mixed market in this region. While some of the countries have very high-income economies in the Middle East, equipped healthcare systems, most African nations are not so lucky. The resource limitations, political instability, and weak infrastructure are often barriers to proper implementation of effective vaccination programs. However, in recognition of vaccines in these regions, a growing affinity is seen for vaccinations. Vaccination, supported by donor agencies and international organizations, is designed to strengthen healthcare infrastructure and reduce vaccine hesitancy.

Disease Control and Prevention Vaccine Market Report Scope:

Attribute	Details
Market Size 2024	USD 9.0 Billion
Projected Market Size 2034	USD 10.3 Billion
CAGR Growth Rate	1.5%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Vaccine Type- Monovalent Vaccine and Multivalent Vaccine Product Type- Live-attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Toxoid Vaccines By Age Group- Pediatric, and Adults By Application- Infectious Disease, Cancer, and Other Indication
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report Coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on By Vaccine Type, By Product type, By Age Group, By Application, and Region.

By Vaccine Type:

• Monovalent Vaccine
• Multivalent Vaccine

By Product type:

• Live-attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines

By Age Group:

• Pediatric
• Adults

By Application:

• Infectious Disease
• Cancer
• Other Indication

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Disease Control and Prevention Vaccine Market include AstraZeneca PLC, Sinovac Biotech Ltd., Astellas Pharma Inc., Serum Institute of India Pvt. Ltd., Daiichi Sankyo.GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., and Sanofi S.A.

• In August 2022, AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, was approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection.
• In June 2022, The United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorization for the VBI Vaccines' PreHevbri (Hepatitis B vaccine (recombinant, adsorbed)) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. The vaccine is expected to be launched in 2023 in the United Kingdom.

• AstraZenca Plc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sinovac Biotech Ltd.
• Astellas Pharma Inc.
• Serum Institute of India Pvt. Ltd.
• Daiichi Sankyo.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.,
• Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Vaccine type
  • Market Snippet, By Product type
  • Market Snippet, By Age group
  • Market Snippet, By Application
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Vaccine type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Monovalent Vaccine
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Multivalent Vaccine
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Product type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Live-attenuated Vaccines
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Inactivated Vaccines
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Recombinant Vaccines
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• Toxoid Vaccines
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Age group, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Pediatric
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Adult
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Application, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Infectious Disease
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Aged group, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Aged group, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Aged group, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Aged group, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Aged group, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• AstraZenca Plc.
• Sinovac Biotech Ltd.
• Astellas Pharma Inc.
• Serum Institute of India Pvt. Ltd.
• Daiichi Sankyo.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.,
• Sanofi S.A.

The Last Word

• Future Impact
• About Us
• Contact